• Seres Therapeutics Inc MCRB.OQ reported a quarterly adjusted loss of $2.96​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-5.40. The mean expectation of five analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from $-3.00 to $5.60 per share.

• Reported revenue was zero​; analysts expected $10.00 million.

• Seres Therapeutics Inc's reported EPS for the quarter was $3.75​.

• The company reported quarterly net income of $32.68 million.

• Seres Therapeutics Inc shares had fallen by 38.9% this quarter and lost 48.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 83.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Seres Therapeutics Inc is $73.70

This summary was machine generated from LSEG data May 7 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)